Teacher Retirement System of Texas Invests $330,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Teacher Retirement System of Texas purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,905 shares of the company’s stock, valued at approximately $330,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vontobel Holding Ltd. purchased a new stake in TransMedics Group in the first quarter valued at approximately $291,000. New York State Teachers Retirement System grew its holdings in TransMedics Group by 183.2% in the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock valued at $1,477,000 after purchasing an additional 14,200 shares during the period. Emerald Advisers LLC grew its holdings in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after purchasing an additional 220,804 shares during the period. Sugar Maple Asset Management LLC purchased a new stake in TransMedics Group in the first quarter valued at approximately $740,000. Finally, Capital Fund Management S.A. grew its holdings in TransMedics Group by 940.3% in the fourth quarter. Capital Fund Management S.A. now owns 125,880 shares of the company’s stock valued at $7,849,000 after purchasing an additional 113,780 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TMDX shares. Oppenheimer lifted their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research report on Tuesday, June 17th. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average price target of $129.88.

TransMedics Group Stock Down 2.3%

TransMedics Group stock opened at $109.88 on Friday. The company has a 50-day simple moving average of $127.13 and a 200-day simple moving average of $92.25. The firm has a market capitalization of $3.72 billion, a P/E ratio of 80.79 and a beta of 2.06. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company’s quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.35 earnings per share. As a group, equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the company’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Weill sold 732 shares of the company’s stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director owned 12,134 shares of the company’s stock, valued at $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,418 shares of company stock worth $1,512,613. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.